

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number  
**WO 01/68110 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 35/26**, 39/395, 51/00, A01N 1/02, C07K 16/00, C12M 1/34, C12N 5/00, 5/06, 5/08, 13/00, G01N 1/30
- (21) International Application Number: PCT/US01/07506
- (22) International Filing Date: 9 March 2001 (09.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/524,164 13 March 2000 (13.03.2000) US
- (71) Applicant: ONCOSIS [US/US]; Suite 111, 6199 Cornerstone Court, San Diego, CA 92121 (US).
- (72) Inventors: **KOLLER, Manfred, R.**; 3646 Torrey View Court, San Diego, CA 92130 (US). **PALSSON, Bernhard, O.**; 730 Fern Glen, La Jolla, CA 92037 (US). **EISFELD, Timothy, M.**; Apt. E, 8525 Villa La Jolla, La Jolla, CA 92037 (US).
- (74) Agent: **HUNT, Dale, C.**; Knobbe, Martens, Olson & Bear, LLP, 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/68110 A1

(54) Title: METHOD AND APPARATUS FOR INDUCING A CELLULAR RESPONSE

(57) Abstract: A method and apparatus are provided to induce a response in cells by illuminating cells to determine which are labeled with a first label with a first wavelength of light and which are labeled with other labels with other wavelengths of light. Then the selected cells may be targeted for treatment that results in a response in the selected cells only.

**METHOD AND APPARATUS FOR INDUCING A CELLULAR RESPONSE**Background of the Invention*Field of the Invention*

5           This invention relates to methods and apparatus for selectively targeting specific cells within a mixed population of living cells. In particular, this invention relates to methods and apparatus for selectively identifying, and individually targeting with an energy beam, specific cells within a mixed cell population to induce a response in the targeted cells.

*Description of the Related Art*

10           The use of cellular therapies is growing rapidly, and is therefore becoming an important therapeutic modality in the practice of medicine. Unlike other therapies, cellular therapies achieve a long-lasting, and often permanent benefit through the use of living cells. Hematopoietic stem cell (HSC) (*e.g.*, bone marrow or mobilized peripheral blood) transplantation is one example of a practiced, insurance-reimbursed cellular therapy. Many other cellular therapies are being developed, including immunotherapy for cancer and infectious diseases, chondrocyte therapy for cartilage defects, neuronal cell therapy for neurodegenerative diseases, and stem cell therapy for numerous indications. Many  
15 of these therapies require the removal of unwanted, detrimental cells for full efficacy to be realized.

          Gene therapy is another active area of developing medicine that can influence the success of cellular therapy. Given the rapid advances in the understanding of the human genome, it is likely that many genes will be available for insertion into cells prior to transplantation into patients. However, obtaining efficient targeted delivery of  
20 genes into specific cells of interest has remained a difficult obstacle in the development of these therapies.

          In the treatment of cancer, it has been found that high-dose chemotherapy and/or radiation therapy can be used to selectively kill rapidly dividing cancer cells in the body. Unfortunately, several other cell types in the body are also rapidly dividing, and in fact, the dose-limiting toxicity for most anti-cancer therapies is the killing of HSCs and progenitor cells in the bone marrow. HSC transplantation was developed as a therapy to rescue the hematopoietic  
25 system following anti-cancer treatments. Upon infusion, the HSCs and progenitor cells within the transplant selectively home to the bone marrow and engraft. This process is monitored clinically through daily blood cell counts.

          Once blood counts return to acceptable levels, usually within 20 to 30 days, the patient is considered engrafted and is released from the hospital.

          HSC transplants have been traditionally performed with bone marrow, but mobilized peripheral blood  
30 (obtained via leukapheresis after growth factor or low-dose chemotherapy administration) has recently become the preferred source because it eliminates the need to harvest approximately one liter of bone marrow from the patient. In addition, HSCs from mobilized peripheral blood result in more rapid engraftment (8 to 15 days), leading to less critical patient care and earlier discharge from the hospital. HSC transplantation has become an established therapy for treating many diseases, such that over 45,000 procedures were performed worldwide in 1997.

HSC transplantation may be performed using either donor cells (allogeneic), or patient cells that have been harvested and cryopreserved prior to administration of high-dose anti-cancer therapy (autologous). Autologous transplants are widely used for treating a variety of diseases including breast cancer, Hodgkin's and non-Hodgkin's lymphomas, neuroblastoma, and multiple myeloma. The number of autologous transplants currently outnumbers  
 5 allogeneic transplants by approximately a 2:1 ratio. This ratio is increasing further, mainly due to graft-versus-host disease (GVHD) complications associated with allogeneic transplants. One of the most significant problems with autologous transplants is the reintroduction of tumor cells to the patient along with the HSCs, because these tumor cells contribute to relapse of the original disease.

As a tumor grows, tumor cells eventually leave the original tumor site and migrate through the bloodstream  
 10 to other locations in the body. This process, called tumor metastasis, results in the formation and growth of satellite tumors that greatly increase the severity of the disease. The presence of these metastatic tumor cells in the blood and other tissues, often including bone marrow, can create a significant problem for autologous transplantation. In fact, there is a very high probability that metastatic tumor cells will contaminate the harvested HSCs that are to be returned to the patient following anti-cancer therapy.

The presence of contaminating tumor cells in autologous bone marrow and mobilized peripheral blood  
 15 harvests has been confirmed in numerous scientific studies. Tumor cell contamination has been repeatedly observed in patients with T-cell lymphoma, non-Hodgkin's lymphoma, leukemia, neuroblastoma, lung cancer, breast cancer, etc. (Brugger, W., Bross, K. J., Glatt, M., Weber, F., Mertelsmann, R., and Kanz, L.: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. *Blood* 83: 636-640, 1994; Gulati, S.  
 20 C. and Acaba, L.: Rationale for purging in autologous stem cell transplantation. *J.Hematotherapy* 2: 467-471, 1993; Kvalheim, G., Holte, H., Jakobsen, E., and Kvaloy, S.: Immunomagnetic purging of lymphoma cells from autografts. *J.Hematotherapy* 5: 561-562, 1996; Mapara, M. Y., Körner, I. J., Hildebrandt, M., Bargou, R., Kahl, D., Reichardt, P., and Dörken, B.: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse  
 25 transcriptase-polymerase chain reaction. *Blood* 89: 337-344, 1997; Paulus, U., Dreger, P., Viehmann, K., von Neuhoff, N., and Schmitz, N.: Purging peripheral blood progenitor cell grafts from lymphoma cells: Quantitative comparison of immunomagnetic CD34<sup>+</sup> selection systems. *Stem Cells* 15: 297-304, 1997; Shpall, E. J. and Jones, R. B.: Release of tumor cells from bone marrow. *Blood* 83: 623-625, 1994; Vervordeldonk, S. F., Merle, P. A., Behrendt, H., Steenbergen, E. J., van den Berg, H., van Wering, E. R., von dem Borne, A. E. G., van der Schoot, C. E., van Leeuwen,  
 30 E. F., and Slaper-Cortenbach, I. C. M.: PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukemia. *Br.J.Haematol.* 96: 395-402, 1997). In every study, all or nearly all of the patient samples analyzed were positive for tumor contamination. The level of tumor cell burden in these HSC harvests varied widely depending upon the type and stage of disease. Typical numbers indicate that tumor cells are present in the range of 3 to 3,000 tumor cells per  
 35 million hematopoietic cells. Since the transplanted cell number is on the order of 10 billion hematopoietic cells, the

total number of tumor cells in a transplant varies in the range of 30 thousand to 30 million. The reinfusion of this number of tumor cells in the HSC transplant following the patient's anti-cancer therapy is of considerable clinical concern. In fact, animal models have shown that as few as 25 leukemia cells can establish a lethal tumor in 50% of mice, and these numbers extrapolate to 3500 cells in humans (Gulati, Acaba 1993).

5           Recent landmark studies have unambiguously shown that reinfused tumor cells do indeed contribute to disease relapse in humans (Rill, D. R., Santana, V. M., Roberts, W. M., Nilson, T., Bowman, L. C., Krance, R. A., Heslop, H. E., Moen, R. C., Ihle, J. N., and Brenner, M. K.: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. *Blood* 84: 380-383, 1994). This was proven by genetically marking the harvested cells prior to transplant, and then showing that the marker was detected  
10 in resurgent tumor cells in those patients who relapsed with disease. These data have been confirmed by other investigators (Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., Ellerson, D., Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Hester, J., Korbling, M., Durett, A., Moen, R., Berenson, R., Heimfeld, S., Hamer, J., Calver, L., Tibbits, P., Talpaz, M., Kantarjian, H., Champlin, R., and Reading, C.: Genetic marking shows that Ph<sup>+</sup> cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous  
15 bone marrow transplantation in CML. *Blood* 83: 3068-3076, 1994), indicating that contaminating tumor cells in HSC transplants represent a real threat to patients undergoing autologous transplantation.

Subsequent detailed studies have now shown that the actual number of tumor cells reinfused in the transplant was correlated with the risk of relapse for acute lymphoblastic leukemia (Vervoordeldonk et al. 1997), non-Hodgkin's lymphoma (Sharp, J. G., Joshi, S. S., Armitage, J. O., Bierman, P., Coccia, P. F., Harrington, D. S.,  
20 Kessinger, A., Crouse, D. A., Mann, S. L., and Weisenburger, D. D.: Significance of detection of occult Non-Hodgkin's Lymphoma in histologically uninvolved bone marrow by a culture technique. *Blood* 79: 1074-1080, 1992; Sharp, J. G., Kessinger, A., Mann, S., Crouse, D. A., Armitage, J. O., Bierman, P., and Weisenburger, D. D.: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. *J.Clin.Oncol.* 14: 214-219, 1996), mantle cell lymphoma (Andersen, N. S., Donovan, J.  
25 W., Borus, J. S., Poor, C. M., Neuberg, D., Aster, J. C., Nadler, L. M., Freedman, A. S., and Gribben, J. G.: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection in minimal residual disease. *Blood* 90: 4212-4221, 1997), and breast cancer (Brockstein, B. E., Ross, A. A., Moss, T. J., Kahn, D. G., Hollingsworth, K., and Williams, S. F.: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.  
30 *J.Hematotherapy* 5: 617-624, 1996; Fields, K. K., Elfenbein, G. J., Trudeau, W. L., Perkins, J. B., Janssen, W. E., and Moscinski, L. C.: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. *J.Clin.Oncol.* 14: 1868-1876, 1996; Schulze, R., Schulze, M., Wischnik, A., Ehle, S., Doukas, K., Behr, W., Ehret, W., and Schlimok, G.: Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk  
35 breast cancer patients. *Bone Marrow Transplant.* 19: 1223-1228, 1997; Vannucchi, A. M., Bosi, A., Glinz, S., Pacini,

P., Linari, S., Saccardi, R., Alterini, R., Rigacci, L., Guidi, S., Lombarkini, L., Longo, G., Mariani, M. P., and Rossi-Ferrini, P.: Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. *Br.J.Haematol.* 103: 610-617, 1998; Vredenburgh, J. J., Silva, O., Broadwater, G., Berry, D., DeSombre, K., Tyer, C., Petros, W. P., Peters, W. P., and Bast, J., R.C.: The significance of tumor contamination in the  
 5 bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. *Biol. Blood Marrow Transplant.* 3: 91-97, 1997). One of these studies went even further, showing that the number of tumor cells infused was inversely correlated with the elapsed time to relapse (Vredenburgh et al. 1997). These data suggest that reducing the number of tumor cells in the transplant will lead to better outcomes for the patient.

10 In fact, one clinical study of NHL purging in 114 patients showed that disease-free survival (after a median 2-year follow-up) was substantially higher (93%) in the subset of patients that had all detectable tumor cells purged prior to transplant, as compared with those in which purging was unsuccessful (54%) (Gribben, J. G., Freedman, A. S., Neuberg, D., Roy, D. C., Blake, K. W., Woo, S. D., Grossbard, M. L., Rabinowe, S. N., Coral, F., Freeman, G. J., Ritz, J., and Nadler, L. M.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation  
 15 for B-cell lymphoma. *N.E.J.Med.* 325: 1525-1533, 1991). In a recent update of this study, eight-year freedom-from-relapse was shown to be 83% in the subset of patients that had all detectable tumor cells purged, as compared to 19% in patients where purging was unsuccessful (Freedman, A. S., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K.C., Fisher, D. C., Schlossman, R., Alyea, E. P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L. M., and Gribben, J. G.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular  
 20 lymphoma. *Blood* 94: 3325-3333, 1999). Therefore, the actual number of tumor cells in an HSC transplant, and the ability to reliably purge them, are of significant and growing importance in the delivery of HSC transplantation therapies for cancer patients.

Due to the known risk of tumor cell contamination in autologous transplantation, a number of methods have been proposed for removing contaminating tumor cells from harvested HSC populations. The basic principle underlying  
 25 all purging methods is to remove or kill tumor cells while preserving the HSCs that are needed for hematopoietic reconstitution in the patient.

One method based on relatively non-specific adhesion differences of hematopoietic cells in deep bed filtration has been described by Dooley, et al. (Dooley, D. C., Xiao, M., Wickramasinghe, S. R., Oppenlander, B. K., and Castino, F.: A novel inexpensive technique for the removal of breast cancer cells from mobilized peripheral blood stem  
 30 cell products. *Blood* 88: 252a, 1996). An elutriation method based on relatively non-specific cell size and density differences has been described by Wagner, et al. (Wagner, J. E., Collins, D., Fuller, S., Schain, L. R., Berson, A. E., Almici, C., Hall, M. A., Chen, K. E., Okarma, T. B., and Lebkowski, J. S.: Isolation of small, primitive human hematopoietic stem cells: Distribution of cell surface cytokine receptors and growth in SCID-Hu mice. *Blood* 86: 512-523, 1995). Preferential killing of tumor cells by hyperthermia has been described by Higuchi, et al. (Higuchi, W.,  
 35 Moriyama, Y., Kishi, K., Koike, T., Shibata, A., Shinada, S., Tada, I., and Miura, A.: Hematopoietic recovery in a patient

with acute lymphoblastic leukemia after an autologous marrow graft purged by combined hyperthermia and interferon in vitro. *Bone Marrow Transplant.* 3: 163-166, 1991). These relatively non-specific methods reduce the number of tumor cells present, but a significant number are known to remain.

5 In another method, cytotoxic agents, such as 4-hydroxy-peroxy-cyclophosphamide (4-HC), were used to preferentially kill tumor cells in populations containing HSCs (Bird, J. M., Luger, S., Mangan, P., Edelstein, M., Silberstein, L., Powlis, W., Ball, J., Schultz, D. J., and Stadtmauer, E. A.: 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of none marrow involvement. *BMT* 18: 309-313, 1996). Unfortunately, collateral damage to normal HSCs was so severe that patient engraftment was delayed by as much as 59 days.

10 Another method employed preferential killing of tumor cells by exposing all cells to photoradiation in the presence of a light-sensitizing agent (e.g. merocyanide) (Gulliya, K. S. and Pervaiz, S.: Elimination of clonogenic tumor cells from HL-60, Daudi, and U-937 cell lines by laser photoradiation therapy: Implications for autologous bone marrow purging. *Blood* 73: 1059-1065, 1989). Although more tumor cells were killed than hematopoietic cells, some tumor cells still remained, and HSC damage was significant.

15 Another method for removing tumor cells from populations of hematopoietic cells involved immunoconjugating a toxic agent to an antibody having specificity for the tumor cells. In this system, antibodies were bound to chemotoxic agents, toxins, or radionucleides and then contacted with the total cell population. Unfortunately, not all of the tumor cells were killed by this treatment (Gribben et al. 1991; Robertson, M. J., Soiffer, R. J., Freedman, A. S., Rabinowe, S. L., Anderson, K. C., Ervin, T. J., Murray, C., Dear, K., Griffin, J. D., Nadler, L. M.,  
20 and Ritz, J.: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. *Blood* 79: 2229-2236, 1992).

Some companies and physicians have attempted to purge malignant cells from populations of non-tumor cells using an immunoaffinity bead-based selection. In this procedure, the total cell population is contacted by  
25 immunoaffinity beads. For example, a first (positive) CD34-selection procedure enriches HSCs from the tumor cell-containing hematopoietic cell mixture. In some instances, a second (negative) immunoaffinity bead-based selection is also performed using anti-tumor or anti-epithelial cell antibodies attached to the beads. Although these procedures enrich HSCs and reduce tumor cell numbers, tumor cells can still be detected in the final product (Mapara, M. Y., Korner, I. J., Lentzsch, S., Krah, D., Reichardt, P., and Dorken, B.: Combined positive/negative purging and  
30 transplantation of peripheral blood progenitor cell autografts in breast cancer patients: A pilot study. *Exp.Hematol.* 27: 169-175, 1999)

In another protocol, Clarke et al. disclosed the use of adenovirus-mediated transfer of suicide genes to selectively kill tumor cells (Clarke, M. F., Apel, I. J., Benedict, M. A., Eipers, P. G., Sumantran, V., González-García, M., Doedens, M., Fukunaga, N., Davidson, B., Dick, J. E., Minn, A. J., Boise, L. H., Thompson, C. B., Wicha, M., and Nunez,  
35 G.: A recombinant *bcl-2*<sub>S</sub> adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.

*PNAS* 92: 11024-11028, 1995). However, it is well known that virus-mediated gene transfer is far less than 100% efficient, which would result in a significant number of tumor cells being unaffected by the protocol.

Yet another method utilized fluorescence-activated cell sorting (FACS) to sort HSCs from tumor cells (Tricot, G., Gazitt, Y., Jagannath, S., Vesole, D., Reading, C. L., Juttner, C. A., Hoffman, R., and Barlogie, B.: CD34<sup>+</sup>Thy<sup>+</sup>lin<sup>-</sup> peripheral blood stem cells (PBSC) effect timely trilineage engraftment in multiple myeloma (MM). *Blood* 86: 293a-D, 1995). As is known, flow cytometry sorts cells one at a time and physically separates one population of cells from a mixture of cells based upon cell surface markers and physical characteristics. However, it has been shown that using FACS to separate large cell populations for clinical applications is not advantageous because the process is slow, the cell yields can be very low, and purity greater than ~98% is rarely achieved.

Another method utilizing a flow cytometer is described in U.S. Patent No. 4,395,397 to Shapiro. In the Shapiro method, labeled cells are placed in a flow cytometer, and a downstream laser beam is used to kill the labeled cells in the flowing stream after they pass by the detector and are recognized as being labeled by an electronic system. This method suffers from a number of disadvantages. Firstly, once an unwanted cell has passed through the detector/laser region there is no way to check that destruction has been completed successfully. If a tumor cell evades destruction it will inevitably be reintroduced into the patient. Secondly, the focal spot diameter of the laser beam is of necessity greater than the liquid stream cross section. Accordingly, many of the HSCs in the region of an unwanted cell will also be destroyed by the laser beam. Also, as described above, flow cytometric techniques do not provide pure samples of unlabeled cells due to the random and dynamic nature of the heterogeneous cell mixture that is flowing in a fast-moving (1-20 m/sec) stream of liquid.

Another method that utilizes laser technology is described in U.S. Patent No. 4,629,687 to Schindler, et al. In this method, anchorage-dependent cells are grown on a movable surface. A small laser beam spot is scanned across the moving surface to illuminate cells one at a time and the information is then recorded. The same laser is then switched to a lethal power level, and the beam is swept over the surface in all areas except where a cell of interest was recorded during the illumination step. Unfortunately, this method is slow and only will work on cells that can adhere to a surface.

A still further method that utilizes laser technology is described in U.S. Patent No. 5,035,693 to Kratzer. In this method, cells are placed on a moving belt and a small laser beam spot is scanned across the belt surface. When a particular cell radiates in response to the illuminating laser spot, the same laser is quickly switched to a high power setting in order to kill the cell in a near simultaneous manner before the laser has moved appreciably away from that cell. However, this system has many of the same disadvantages as the Shapiro method. For example, because the scanner is continuously moving during the imaging and killing process, the system is highly-dynamic, and therefore less stable and less accurate than a static system. Also, because the cells are moving on a belt past the detector in one direction, the method is not reversible. Thus, if a single tumor cell escapes detection, it will be reintroduced into the patient.

Others have used a small laser beam spot to dynamically scan over a surface to illuminate cells. For example, U.S. Patent No. 4,284,897 to Sawamura et al. describes the use of galvanometric mirrors to scan a small laser beam spot in a standard microscope to illuminate fluorescent cells. U.S. Patent No. 5,381,224 to Dixon et al. describes imaging of macroscopic specimens through the use of a laser beam spot that is raster-scanned with galvanometric mirrors through an F-theta scanning lens. In U.S. Patent Nos. 5,646,411, 5,672,880, and 5,719,391 to Kain, scanning of a small laser spot with galvanometers through an F-theta lens is described. All of these imaging methods dynamically illuminate a small point that is moved over the surface to be imaged. In some cases, the surface being scanned also moves during imaging.

Similar methods of scanning a small laser spot have been described for purposes other than imaging of cells. For example, U.S. Patent No. 4,532,402 to Overbeck describes the use of galvanometers to move a small laser beam spot over a semiconductor surface for repair of an integrated circuit. Similarly, U.S. Patent No. 5,690,846 to Okada et al. describes laser processing by using mirrors to move a small laser spot through an F-theta scanning lens. U.S. Patent No. 5,296,963 to Murakami et al. describes the use of galvanometric mirrors to scan a small laser beam spot in a standard inverted microscope to puncture cells for insertion of genetic matter.

Yet another method of scanning a biological specimen is described in U.S. Patent No. 5,932,872 to Price. This method uses a plurality of detectors to simultaneously capture images at a plurality of focal planes from a constantly moving surface. The resultant images were used to choose the best-focus image in real-time in order to generate a three-dimensional volumetric image of a specimen.

The majority of methods described above are based on administering a tumor cell-removal or tumor cell-killing strategy to the entire harvested cell population as a whole. In flow cytometry, cells are sorted on a single cell basis to physically separate the unwanted tumor cells from HSCs. While each of these methods has been shown to reduce tumor cell numbers in HSC transplants, none has demonstrated the ability to remove or kill all detectable tumor cells. In fact, the majority of patient transplants still contain detectable tumor cells after these purging techniques are used. Approximately 30 to 30,000 tumor cells per transplant still remain, even after multiple-step purging procedures (Gazitt, Y., Reading, C. C., Hoffman, R., Wickrema, A., Vesole, D. H., Jagannath, S., Condino, J., Lee, B., Barlogie, B., and Tricot, G.: Purified CD34<sup>+</sup>lin<sup>-</sup>Thy<sup>+</sup> stem cells do not contain clonal myeloma cells. *Blood* 86: 381-389, 1995; Gribben et al. 1991; Mapara et al. 1997; Paulus et al. 1997).

Further, all of these methods result in some degree of HSC loss or damage, which can significantly impact the success of the HSC transplant by delaying patient engraftment. In summary, existing technologies for separating one cell population from another are inadequate, and there exists a great unmet clinical need for novel approaches that can effectively separate and treat one selected cell population within a second cell population. The method and apparatus described herein fulfills this need.

#### Summary of the Invention

This invention provides a high-speed method and apparatus for selectively identifying, and individually targeting with an energy beam, specific cells within a mixed cell population of cells for the purpose of inducing a



response in the targeted cells. Using the apparatus of the present invention, every detectable target cell in a mixed cell population can be specifically identified and targeted, without substantially affecting cells that are not being targeted.

5 Specific cells are identified with the disclosed invention using several approaches. One embodiment includes a non-destructive labeling method so that all of the target cells are substantially distinguishable from the non-target cells in the specimen. In this embodiment, a labeled antibody can be used to specifically mark each target cell, yet not mark non-target cells. The labeled cells are then identified within the cell mixture. A narrow energy beam is thereafter focused on the first of the targeted cells to achieve a desired response. The next of the targeted cells is then irradiated, and so on until every targeted cell has been irradiated.

10 In another embodiment, an antibody that selectively binds to non-target cells, but not to target cells, is used to identify the target cells by the absence of the label, and target cells are thereafter individually targeted with the energy beam.

To provide even greater flexibility in the ability to distinguish target cells from non-target cells, combinations of two or more labels, each with different fluorescent properties, can be used. For example, one antibody labeled with phycoerythrin (PE) and another antibody labeled with Texas Red® could be used to identify target cells that express one, both, or neither of the antigens recognized by the antibodies. One skilled in the art could propose the use of many multi-color labeling approaches to identify specific cell subpopulations within a complex mixture of cells.

20 The nature of the response that is induced by the energy beam is dependent upon the nature of the energy beam. Responses that can be induced with an energy beam include necrosis, apoptosis, optoporation (to allow entry of a substance that is present in the surrounding medium, including genetic material), cell lysis, cell motion (laser tweezers), cutting of cell components (laser scissors), activation of a photosensitive substance, excitation of a fluorescent reagent, etc.

One embodiment of the invention is an apparatus for selectively inducing a response in one or more targeted cells within a biological specimen that includes: an illumination source for illuminating a frame of cells in the biological specimen with a first wavelength of light; an image capture system that captures one or more images of the frame of cells; first commands for determining the locations of the one or more targeted cells within the frame of cells; an energy source that emits an energy beam sufficient to induce the response in at least one of the one or more targeted cells within the frame of cells; and second commands for steering the energy beam to the locations of the one or more targeted cells.

30 Still another embodiment of the invention is an apparatus for selectively inducing a response in one or more targeted cells within a biological specimen. This embodiment includes a first illumination source for illuminating a frame of cells in the biological specimen with a first wavelength of light; a second illumination source for illuminating a frame of cells in the biological specimen with a second wavelength of light; an image capture system that captures one or more images of the frame of cells; first commands for determining the locations of the one or more targeted cells within the frame of cells; an energy source that emits an energy beam sufficient to induce the response in at

least one of the one or more targeted cells within the frame of cells; and second commands for steering the energy beam to the locations of the one or more targeted cells.

A still further embodiment is an apparatus for selectively inducing a first response in a first targeted cell population and a second response in a second targeted cell population within a biological specimen, providing: a means  
5 for illuminating a frame of cells in the biological specimen with one or more wavelengths of light; an image capture system that captures one or more images of the first targeted cell population and the second targeted cell population; first commands for determining the coordinates of one or more cells within the first targeted cell population and one or more cells within the second targeted cell population by reference to the captured one or more images; an energy source that emits an energy beam; and second commands for steering the energy beam to the coordinates.

10 One additional embodiment is an apparatus for monitoring the status of labeled cells within a biological sample. This embodiment includes: an illumination source for illuminating a population of cells in the biological sample so that the labeled cells are distinguishable from non-labeled cells; an image capture system that captures one or more images of the illuminated population of cells; first commands for determining the locations of labeled cells in the one or more images; a memory for storing the locations of the labeled cells in the biological sample;  
15 an energy source that emits a first energy beam to illuminate a first labeled cell; and a detector for measuring the fluorescence of the first labeled cell in response to illumination by the energy beam.

A further embodiment is a method for selectively inducing a response in one or more targeted cells within a biological specimen that includes: illuminating a frame of cells in the biological specimen with a first wavelength of light, wherein the biological specimen has been treated with one or more labels that, when excited by the first  
20 wavelength of light, emit energy at a one or more different wavelengths; capturing an image of the frame of cells; determining the locations of one or more targeted cells within the image by reference to cells that are activated by the first wavelength of light; and steering an energy beam to the locations of the one or more targeted cells, wherein the energy beam is sufficient to induce a response in at least one of the one or more targeted cells.

Yet a further embodiment is a method for inducing a first response in a first targeted population of cells and  
25 a second response in a second targeted population of cells, comprising: illuminating the first targeted population of cells and the second targeted population of cells with a first wavelength of light; capturing an image comprising the illuminated first targeted population of cells and the illuminated second targeted population of cells; determining the locations of the first targeted population of cells by reference to the image; determining the locations of the second targeted population of cells by reference to the image; and steering an energy beam to the locations of the first  
30 targeted population of cells and the second targeted population of cells in order to induce the first response in the first targeted population of cells and the second response in the second targeted population of cells.

A large number of commercially important research and clinical applications can be envisioned for such an apparatus, examples of which are presented below.

Brief Description of the Drawings

FIGURE 1 is a perspective view of one embodiment of a cell treatment apparatus and illustrates the outer design of the housing and display.

FIGURE 2 is a perspective view of one embodiment of a cell treatment apparatus with the outer housing removed and the inner components illustrated.

FIGURE 3 is a block diagram of the optical subassembly design within one embodiment of a cell treatment apparatus.

FIGURE 4 is a perspective view of one embodiment of an optical subassembly within one embodiment of a cell treatment apparatus.

FIGURE 5 is a side view of one embodiment of an optical subassembly that illustrates the arrangement of the scanning lens and the movable stage.

FIGURE 6 is a bottom perspective view of one embodiment of an optical subassembly.

FIGURE 7 is a top perspective view of the movable stage of the cell treatment apparatus.

Detailed Description

A method and apparatus is described for selectively identifying, and individually targeting with an energy beam, specific cells within a mixed cell population for the purpose of inducing a response in the targeted cells. Generally, the method first employs a label or labels that act as markers to identify and locate specific cells within a cell mixture.

Use of one label leads to the identification of at least two cell subpopulations; cells expressing the label, and cells lacking the label. Additional subpopulations can be further identified by the degree of label expression. For example, cells with bright expression or dim expression can be distinguished. In addition, one can detect other observable cell parameters, such cell shape or size. Use of additional labels that are excited, or emit light, at different wavelengths, allows greater flexibility for identifying many cell subpopulations within the mixture.

Many such labels are available for cell identification. For example, monoclonal antibodies that are directly or indirectly tagged with a fluorochrome can be used as specific labels. Other examples of cell surface binding labels include non-antibody proteins, lectins, carbohydrates, or short peptides with selective cell binding capacity. Membrane intercalating dyes, such as PKH-2 and PKH-26 (Sigma, St. Louis, MO), also serve as useful distinguishing labels indicating mitotic history of a cell. Many membrane-permeable reagents are also available to distinguish living cells from one another based upon selected criteria. For example, phalloidin indicates membrane integrity, tetramethyl rhodamine methyl ester (TMRM) indicates mitochondrial transmembrane potential, monochlorobimane indicates glutathione reductive stage, carboxymethyl fluorescein diacetate (CMFDA) indicates thiol activity, carboxyfluorescein diacetate indicates intracellular pH, fura-2 indicates intracellular  $\text{Ca}^{2+}$  level, and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolo carbocyanine iodide (JC-1) indicates membrane potential. Cell viability can be assessed by the use of fluorescent SYTO 13 or YO PRO reagents (Molecular Probes, Eugene, OR). Similarly, a fluorescently-tagged genetic probe (DNA or RNA) could be used to label cells which carry a gene of interest, or express a gene of interest.

Further, cell cycle status can be assessed through the use of Hoechst 33342 dye to label existing DNA combined with bromodeoxyuridine (BrdU) to label newly synthesized DNA. It should be noted that the absence of a label can also be used for identifying target cells.

5 It should be realized that embodiments of the invention include the use of several fluorochromes simultaneously. Preferably, each fluorochrome is excited by a single wavelength of light, but emits energy at different light wavelengths. Thus, a color camera that can distinguish emissions at various light wavelengths can advantageously determine which cells in the population have one or more specific labels attached.

Accordingly, embodiments of the invention also include a camera that images a plurality of colors so that combinations of labels can be imaged simultaneously. For example, in one embodiment, a color CCD camera is used to  
10 capture a color image of a population of cells. Because different cells within a population can be targeted by compounds that fluoresce at different wavelengths of light, images can be gathered that distinguish, on the basis of fluorescence wavelength, various cell types in a mixed population. For example, the identity of a cancer cell can be confirmed by its binding to a plurality of compounds that, when excited by an illumination laser, fluoresce at two different wavelengths. A camera that detects both fluorescent molecules is able to confirm the identity of the cancer  
15 cell more reliably than if the system only relied on a single identifying compound. It should be understood that each fluorescent compound might be excited by a different wavelength of light. Thus, embodiments of the system include illumination lasers that emit light at different wavelengths of light. Other embodiments of the system include two or more illumination lasers that each emit light of a chosen wavelength.

After target cells are identified by reference to the one or more labels, an energy beam, such as from a laser,  
20 collimated or focused non-laser light, RF energy, accelerated particle, focused ultrasonic energy, electron beam, or other radiation beam, delivers a targeted dose of energy. The amount of emitted energy is chosen to induce a pre-determined response in each of the targeted cells, without substantially affecting non-targeted cells within the mixture. It is important to note that multiple target subpopulations can be identified, particularly with the use of multiple labels. Further, each target subpopulation can be irradiated with the energy beam in a different manner,  
25 inducing a different response in each target subpopulation.

Figure 1 is an illustration of one embodiment of a cell treatment apparatus 10. The cell treatment apparatus 10 includes a housing 15 that stores the inner components of the apparatus. The housing includes laser safety interlocks to ensure safety of the user, and also limits interference by external influences (e.g., ambient light, dust, etc.). Located on the upper portion of the housing 15 is a display unit 20 for displaying captured images of cell  
30 populations during treatment. These images are captured by a camera, as will be discussed more specifically below. A keyboard 25 and mouse 30 are used to input data and control the apparatus 10. An access door 35 provides access to a movable stage that holds a specimen container of cells undergoing treatment.

An interior view of the apparatus 10 is provided in Figure 2. As illustrated, the apparatus 10 provides an upper tray 200 and lower tray 210 that hold the interior components of the apparatus. The upper tray 200 includes a  
35 pair of intake filters 215A,B that filter ambient air being drawn into the interior of the apparatus 10. Below the

access door 35 is the optical subassembly (not shown). The optical subassembly is mounted to the upper tray 200 and is discussed in detail with regard to Figures 3-6.

On the lower tray 210 is a computer 225 which stores the software programs, commands and instructions that run the apparatus 10. In addition, the computer 225 provides control signals to the treatment apparatus through  
5 electrical signal connections for steering the laser to the appropriate spot on the specimen in order to treat the cells.

As illustrated, a series of power supplies 230A,B,C provide power to the various electrical components within the apparatus 10. In addition, an uninterruptable power supply 235 is incorporated to allow the apparatus to continue functioning through short external power interruptions.

Figure 3 provides a layout of one embodiment of an optical subassembly design 300 within an embodiment  
10 of a cell treatment apparatus 10. As illustrated, an illumination laser 305 provides a directed laser output that is used to excite one or more labels that are attached to targeted cells within the specimen. In this embodiment, the illumination laser emits light at, for example, a wavelength of 532 nm in order to excite one or more specific labels. Of course lasers that illuminate light of other wavelengths could also be used within the system. Once the illumination laser has generated a light beam, the light passes into a shutter 310 which controls the pulse length of the laser light.

After the illumination laser light passes through the shutter 310, it enters a ball lens 315 where it is focused  
15 into an SMA fiber optic connector 320. After the illumination laser beam has entered the fiber optic connector 320, it is transmitted through a fiber optic cable 325 to an outlet 330. By passing the illumination beam through the fiber optic cable 325, the illumination laser 305 can be positioned anywhere within the treatment apparatus and thus is not limited to only being positioned within a direct light pathway to the optical components. In one embodiment, the fiber  
20 optic cable 325 is connected to a vibrating motor 327 for the purpose of mode scrambling and generating a more uniform illumination spot.

After the light passes through the outlet 330, it is directed into a series of condensing lenses in order to  
25 focus the beam to the proper diameter for illuminating one frame of cells. As used herein, one frame of cells is defined as the portion of the biological specimen that is captured within one frame image captured by the camera. This is described more specifically below.

Accordingly, the illumination laser beam passes through a first condenser lens 335. In one embodiment, this  
first lens has a focal length of 4.6 mm. The light beam then passes through a second condenser lens 340 which, in one embodiment, provides a 100 mm focal length. Finally, the light beam passes into a third condenser lens 345, which preferably provides a 200 mm focal length. While the present invention has been described using specific  
30 condenser lenses, it should be apparent that other similar lens configurations that focus the illumination laser beam to an advantageous diameter would function similarly. Thus, this invention is not limited to the specific implementation of any particular condenser lens system.

Once the illumination laser beam passes through the third condenser lens 345, it enters a cube beamsplitter  
350 that transmits the 532 nm wavelength of light emanating from the illumination laser. Preferably, the cube  
35 beamsplitter 350 is a 25.4 mm square cube (Melles-Griot, Irvine, CA). However, other sizes are anticipated to

function similarly. In addition, a number of plate beamsplitters or pellicle beamsplitters could be used in place of the cube beamsplitter 350 with no appreciable change in function.

Once the illumination laser light has been transmitted through the cube beamsplitter 350, it reaches a long wave pass mirror 355 that reflects the 532 nm illumination laser light to a set of galvanometer mirrors 360 that steer  
5 the illumination laser light, under computer control, through a scanning lens (Special Optics, Wharton, NJ) 365 to the specimen (not shown). The galvanometer mirrors are controlled so that the illumination laser light is directed at the proper cell population (i.e. frame of cells) for imaging.

The light from the illumination laser is of a wavelength that is useful for illuminating one or more labels in the specimen. In this embodiment, energy from a continuous wave 532 nm Nd:YAG frequency-doubled laser (B&W Tek,  
10 Newark, DE) reflects off the long wave pass mirror (Custom Scientific, Phoenix, AZ) and excites fluorescent tags (labels) in the specimen. In one embodiment, the fluorescent tag is phycoerythrin (PE). Alternatively, Alexa 532 (Molecular Probes, Eugene, OR) can be used as a fluorescent tag. Phycoerythrin and Alexa 532 have emission spectra with peaks near 580 nm, so that the emitted fluorescent light from the specimen is transmitted via the long wave pass mirror into the camera. The use of the filter in front of the camera blocks light that is not within the wavelength  
15 range of interest, thereby reducing the amount of background light entering the camera.

The 532 nm illumination laser is further capable of exciting multiple fluorochromes that will emit energy at different wavelengths. For example, PE, Texas Red®, and CyChrome™ are all excited by a 532 nm laser. However, they emit energy at 576 nm, 620 nm, and 670 nm, respectively. This difference in emitted wavelengths allows the signal from each fluorochrome to be distinguished from the others. In this case, the range of wavelengths transmitted  
20 by the filter 460 is expanded. In addition, a camera that distinguishes various wavelengths of light is used to capture the emitted light, so that cells which emit different signals are distinguished by the computer. Alternatively, the emitted light from the targeted cells can be directed to three monochromatic cameras, each having a filter to limit its vision to one of the specific fluorochrome's emission wavelengths.

Yet another embodiment involves replacing the single fixed filter 460 with a movable filter wheel that  
25 provides different filters that are moved in and out of the optical pathway. In such an embodiment, fluorescent images of different wavelengths of light are captured at different times during cell processing. The images are then analyzed and correlated by the computer, providing multicolor information about each cell target or the cell population as a whole.

It is generally known that many other devices could be used in this manner to illuminate the specimen,  
30 including, but not limited to, an arc lamp (e.g., mercury, xenon, etc.) with or without filters, a light-emitting diode (LED), other types of lasers, etc. Advantages of this particular laser include high intensity, relatively efficient use of energy, compact size, and minimal heat generation. It is also generally known that other fluorochromes with different excitation and emission spectra could be used in such an apparatus with the appropriate selection of illumination source, filters, and long and/or short wave pass mirrors. For example, Texas Red®, allophycocyanin (APC), and

PharRed™ could all be excited with a 633 nm HeNe illumination laser, whereas fluorescein isothiocyanate (FITC), PE, and CyChrome™ could all be excited with a 488 nm Argon illumination laser.

One skilled in the art could propose many other optical layouts with various components in order to illuminate cells so that they emit fluorescent energy in multiple wavelengths. The illumination sources described above can be used alone or in combination with other sources to provide a wide variety of illumination wavelengths within a single instrument, thereby allowing the use of many distinguishable labels simultaneously.

In addition to the illumination laser 305, a treatment laser 400 is present to irradiate the targeted cells once they have been identified by image analysis. Of course, in one embodiment, the treatment induces necrosis of targeted cells within the cell population. As shown, the treatment laser 400 outputs an energy beam of 523 nm that passes through a shutter 410. Although the exemplary laser outputs an energy beam having a 523 nm wavelength, other sources that generate energy at other wavelengths are also within the scope of the present invention.

Once the treatment laser energy beam passes through the shutter 410, it enters a beam expander (Special Optics, Wharton, NJ) 415 which adjusts the diameter of the energy beam to an appropriate size at the plane of the specimen. Following the beam expander 415 is a half-wave plate 420 which controls the polarization of the beam. The treatment laser energy beam is then reflected off a mirror 425 and enters the cube beamsplitter 350. The treatment laser energy beam is reflected by 90° in the cube beamsplitter 350, such that it is aligned with the exit pathway of the illumination laser light beam. Thus, the treatment laser energy beam and the illumination laser light beam both exit the cube beamsplitter 350 along the same light path. From the cube beamsplitter 350, the treatment laser beam reflects off the long wave pass mirror 355, is steered by the galvanometers 360, thereafter enters the scanning lens 365, and finally is focused upon a targeted cell within the specimen.

It should be noted that a small fraction of the illumination laser light beam passes through the long wave pass mirror 355 and enters a power meter sensor (Gentec, Palo Alto, CA) 445. The fraction of the beam entering the power sensor 445 is used to calculate the level of power emanating from the illumination laser 305. In an analogous fashion, a small fraction of the treatment laser energy beam passes through the cube beamsplitter 350 and enters a second power meter sensor (Gentec, Palo Alto, CA) 446. The fraction of the beam entering the power sensor 446 is used to calculate the level of power emanating from the treatment laser 400. The power meter sensors are electrically linked to the computer system so that instructions/commands within the computer system capture the power measurement and determine the amount of energy that was emitted from the treatment laser.

The energy beam from the treatment laser is of a wavelength that is useful for achieving a response in the cells. In the example shown, a pulsed 523 nm Nd:YLF frequency-doubled laser is used to heat a localized volume of fluid containing the targeted cell, such that it is induced to die within a pre-determined period of time. The mechanism of cell death is dependent upon the actual temperature achieved in the cell, as reviewed by Niemz (Niemz, M. H.: Laser-tissue interactions: Fundamentals and applications. Springer-Verlag, Berlin, 1996).

A Nd:YLF frequency-doubled, solid-state laser (Spectra-Physics, Mountain View, CA) is used because of its stability, high repetition rate of firing, and long time of maintenance-free service. However, most cell culture fluids

and cells are relatively transparent to light in this green wavelength, and therefore a very high fluence of energy is required to achieve cell death. To significantly reduce the amount of energy required, and therefore the cost and size of the treatment laser, in one embodiment a dye is purposefully added to the cell culture to efficiently absorb the energy of the treatment laser in the specimen. In the example shown, the non-toxic dye FD&C red #40 (allura red) is used to absorb the 523 nm energy from the treatment laser. However, one skilled in the art could identify other laser/dye combinations that would result in efficient absorption of energy by the specimen. For example, a 633 nm HeNe laser's energy would be efficiently absorbed by FD&C green #3 (fast green FCF). Alternatively, a 488 nm Argon laser's energy would be efficiently absorbed by FD&C yellow #5 (sunset yellow FCF), and a 1064 nm Nd:YAG laser's energy would be efficiently absorbed by Filtron (Gentex, Zeeland, MI) infrared absorbing dye. Through the use of an energy absorbing dye, the amount of energy required to kill a targeted within a cell population cell can be reduced since more of the treatment laser energy is absorbed in the presence of such a dye.

Another method of achieving thermal killing of cells without the addition of a dye involves the use of an ultraviolet laser. Energy from a 355 nm Nd:YAG frequency-tripled laser will be absorbed by nucleic acids and proteins within the cell, resulting in very localized thermal heating and death.

Yet another method of achieving thermal killing of cells without the addition of a dye involves the use of a near-infrared laser. Energy from a 2100 nm Ho:YAG laser or a 2940 nm Er:YAG laser will be absorbed by water within the cell, resulting in thermal heating and death.

Although this embodiment describes the killing of cells via thermal heating by the energy beam, one skilled in the art would recognize that other responses can also be induced in the cells by an energy beam, including photomechanical disruption, photodissociation, photoablation, and photochemical reactions. Also, a photosensitive substance (e.g., hemtoporphyrin derivative, tin-etio purpurin, lutetium texaphyrin) within the cell mixture could be specifically activated in targeted cells by irradiation. Additionally, a small, transient pore could be made in the cell membrane to allow the entry of genetic or other material. Further, specific molecules in or on the cell, such as proteins or genetic material, could be inactivated by the directed energy beam. These mechanisms of inducing a response in a targeted cell via the use of electromagnetic radiation directed at specific targeted cells are also intended to be incorporated into the present invention.

As discussed above, multiple cell subpopulations can be identified with the appropriate use of specific labels and illumination sources. Further, multiple cellular responses can be induced with the appropriate use of treatment lasers and treatment substances added to the biological specimen. By extension, the simultaneous identification and processing of different cell subpopulations (i.e. to induce different responses) in parallel is possible. For example, one cell subpopulation can be identified and targeted for induction of necrosis, while another cell subpopulation in the same specimen can be targeted for optoporation. As the process is carried out, both cell subpopulations are treated in the appropriate manner, under control of the computer.

In addition to the illumination laser 305 and treatment laser 400, the apparatus includes a camera 450 that captures images (i.e. frames) of the cell populations. As illustrated in Figure 3, the camera 450 is focused through a



lens 455 and filter 460 in order to accurately record an image of the cells without capturing stray background images.

A stop 462 is positioned between the filter 460 and mirror 355 in order to eliminate light that may enter the camera from angles not associated with the image from the specimen. The filter 460 is chosen to only allow passage of light within a certain wavelength range. This wavelength range includes light that is emitted from the targeted cells upon excitation by the illumination laser 305, as well as light from a back-light source 475.

The back-light source 475 is located above the specimen to provide back-illumination of the specimen at a wavelength different from that provided by the illumination laser 305. This LED generates light at 590 nm, such that it can be transmitted through the long wave pass mirror to be directed into the camera. This back-illumination is useful for imaging cells when there are no fluorescent targets within the frame being imaged. An example of the utility of this back-light is its use in attaining proper focus of the system, even when there are only unstained, non-fluorescent cells in the frame. In one embodiment, the back-light is mounted on the underside of the access door 35 (Figure 2).

Thus, as discussed above, the only light returned to the camera is from wavelengths that are of interest in the specimen. Other wavelengths of light do not pass through the filter 460, and thus do not become recorded by the camera 450. This provides a more reliable mechanism for capturing images of only those cells of interest.

It should be noted that in this embodiment, the camera is a charge-coupled device (CCD) and transmits images back to the computer system for processing. As will be described below, the computer system determines the coordinates of the targeted cells in the specimen by reference to the image captured by the CCD camera.

Referring now to Figure 4, a perspective view of an embodiment of an optical subassembly is illustrated. As illustrated, the illumination laser 305 sends a light beam through the shutter 310 and ball lens 315 to the SMA fiber optic connector 320. The light passes through the fiber optic cable 325 and through the output 330 into the condenser lenses 335, 340 and 345. The light then enters the cube beamsplitter 350 and is transmitted to the long wave pass mirror 355. From the long wave pass mirror 355, the light beam enters the computer-controlled galvanometers 360 and is then steered to the proper frame of cells in the specimen through the scanning lens 365.

As also illustrated in the perspective drawing of Figure 4, the treatment laser 400 transmits energy through the shutter 410 and into the beam expander 415. Energy from the treatment laser 400 passes through the beam expander 415 and passes through the half-wave plate 420 before hitting the fold mirror 425, entering the cube beamsplitter 350 where it is reflected 90° to the long wave pass mirror 355, from which it is reflected into the computer controlled galvanometer mirrors 360. After being steered by the galvanometer mirrors 360 through the scanning lens 365, the laser energy beam strikes the proper location within the cell population in order to induce a response in a particular targeted cell.

In order to accommodate a very large surface area of specimen to treat, the apparatus includes a movable stage that mechanically moves the specimen container with respect to the scanning lens. Thus, once a specific sub-population (i.e. field) of cells within the scanning lens field-of-view has been treated, the movable stage brings another sub-population of cells within the scanning lens field-of-view. As illustrated in Figure 5, a computer-controlled movable

stage 500 holds a specimen container (not shown) to be processed. The movable stage 500 is moved by computer-controlled servo motors along two axes so that the specimen container can be moved relative to the optical components of the instrument. The stage movement along a defined path is coordinated with other operations of the apparatus. In addition, specific coordinates can be saved and recalled to allow return of the movable stage to positions of interest. Encoders on the x and y movement provide closed-loop feedback control on stage position.

The flat-field (F-theta) scanning lens 365 is mounted below the movable stage. The scanning lens field-of-view comprises the portion of the specimen that is presently positioned above the scanning lens by the movable stage 500. The lens 365 is mounted to a stepper motor that allows the lens 365 to be automatically raised and lowered (along the z-axis) for the purpose of focusing the system.

As illustrated in Figures 4-6, below the scanning lens 365 are the galvanometer-controlled steering mirrors 360 that deflect electromagnetic energy along two perpendicular axes. Behind the steering mirrors is the long wave pass mirror 355 that reflects electromagnetic energy of a wavelength shorter than 545 nm. Wavelengths longer than 545 nm are passed through the long wave pass mirror, directed through the filter 460, coupling lens 455, and into the CCD camera, thereby producing an image of the appropriate size on the CCD sensor of the camera 450 (See Figures 3 and 4). The magnification defined by the combination of the scanning lens 365 and coupling lens 455 is chosen to reliably detect single cells while maximizing the area viewed in one frame by the camera. Although a CCD camera (DVC, Austin, TX) is illustrated in this embodiment, the camera can be any type of detector or image gathering equipment known to those skilled in the art. The optical subassembly of the apparatus is preferably mounted on a vibration-isolated platform to provide stability during operation as illustrated in Figures 2 and 5.

Referring now to Figure 7, a top view of the movable stage 500 is illustrated. As shown, a specimen container is mounted in the movable stage 500. The specimen container 505 rests on an upper axis nest plate 510 that is designed to move in the forward/backward direction with respect to the movable stage 500. A stepper motor (not shown) is connected to the upper axis nest plate 510 and computer system so that commands from the computer cause forward/backward movement of the specimen container 505.

The movable stage 500 is also connected to a timing belt 515 that provides side-to-side movement of the movable stage 500 along a pair of bearing tracks 525A,B. The timing belt 515 attaches to a pulley (not shown) housed under a pulley cover 530. The pulley is connected to a stepper motor 535 that drives the timing belt 515 to result in side-to-side movement of the movable stage 500. The stepper motor 535 is electrically connected to the computer system so that commands within the computer system result in side-to-side movement of the movable stage 500. A travel limit sensor 540 connects to the computer system and causes an alert if the movable stage travels beyond a predetermined lateral distance.

A pair of accelerometers 545A,B is preferably incorporated on this platform to register any excessive bumps or vibrations that may interfere with the apparatus operation. In addition, a two-axis inclinometer 550 is preferably incorporated on the movable stage to ensure that the specimen container is level, thereby reducing the possibility of gravity-induced motion in the specimen container.

The specimen chamber has a fan with ductwork to eliminate condensation on the specimen container, and a thermocouple to determine whether the specimen chamber is within an acceptable temperature range. Additional fans are provided to expel the heat generated by the electronic components, and appropriate filters are used on the air intakes 215A,B.

5           The computer system 225 controls the operation and synchronization of the various pieces of electronic hardware described above. The computer system can be any commercially available computer that can interface with the hardware. One example of such a computer system is an Intel Pentium II-based computer running the Microsoft Windows® NT operating system. Software is used to communicate with the various devices, and control the operation in the manner that is described below.

10           When the apparatus is first initialized, the computer loads files from the hard drive into RAM for proper initialization of the apparatus. A number of built-in tests are automatically performed to ensure the apparatus is operating properly, and calibration routines are executed to calibrate the cell treatment apparatus. Upon successful completion of these routines, the user is prompted to enter information via the keyboard and mouse regarding the procedure that is to be performed (e.g. patient name, ID number, etc.). Once the required information is entered, the  
15           user is prompted to open the access door 35 and load a specimen onto the movable stage.

          Once a specimen is in place on the movable stage and the door is closed, the computer passes a signal to the stage to move into a home position. The fan is initialized to begin warming and defogging of the specimen. During this time, cells within the specimen are allowed to settle to the bottom surface. In addition, during this time, the apparatus may run commands that ensure that the specimen is properly loaded, and is within the focal range of the  
20           system optics. For example, specific markings on the specimen container can be located and focused on by the system to ensure that the scanning lens has been properly focused on the bottom of the specimen container. After a suitable time, the computer turns off the fan to prevent excess vibrations during treatment, and cell treatment processing begins.

          First, the computer instructs the movable stage to be positioned over the scanning lens so that the first area  
25           (i.e. field) of the specimen to be treated is directly in the scanning lens field-of-view. The galvanometer mirrors are instructed to move such that the center frame within the field-of-view is imaged in the camera. As discussed below, the field imaged by the scanning lens is separated into a plurality of frames. Each frame is the proper size so that the cells within the frame are effectively imaged by the camera.

          The back-light 475 is then activated in order to illuminate the field-of-view so that it can be brought into  
30           focus by the scanning lens. Once the scanning lens has been properly focused upon the specimen, the computer system divides the field-of-view into a plurality of frames so that each frame is analyzed separately by the camera. This methodology allows the apparatus to process a plurality of frames within a large field-of-view without moving the mechanical stage. Because the galvanometers can move from one frame to the next very rapidly compared to the mechanical steps involved in moving the stage, this method results in an extremely fast and efficient apparatus.

In one preferred embodiment, the apparatus described herein processes at least 1, 3, 5, 7, or 9 square centimeters of a biological specimen per minute. In another embodiment, the apparatus described herein processes at least 1, 3, 5, 7, or 9 million cells of a biological specimen per minute. In one other embodiment, the apparatus can preferably induce a response in targeted cells at a rate of 250, 500, 1,000, 2,500, 5,000, or 10,000 cells per second.

5 Initially, an image of the frame at the center of the field-of-view is captured by the camera and stored to a memory in the computer. Instructions in the computer analyze the focus of the specimen by looking at the size of, number of, and other object features in the image. If necessary, the computer instructs the z-axis motor attached to the scanning lens to raise or lower in order to achieve the best focus. The apparatus may iteratively analyze the image at several z-positions until the best focus is achieved. The galvanometer-controlled mirrors are then instructed  
10 to image a first frame, within the field-of-view, in the camera. For example, the entire field-of-view might be divided into 4, 9, 12, 18, 24 or more separate frames that will be individually captured by the camera. Once the galvanometer mirrors are pointed to the first frame in the field-of-view, the shutter in front of the illumination laser is opened to illuminate the first frame through the galvanometer mirrors and scanning lens. The camera captures an image of any fluorescent emission from the specimen in the first frame of cells. Once the image has been acquired, the shutter in  
15 front of the illumination laser is closed and a software program (Epic, Buffalo Grove, IL) within the computer processes the image.

The power sensor 445 discussed above detects the level of light that was emitted by the illumination laser, thereby allowing the computer to calculate if it was adequate to illuminate the frame of cells. If not, another illumination and image capture sequence is performed. Repeated failure to sufficiently illuminate the specimen will  
20 result in an error condition that is communicated to the operator.

Shuttering of illumination light reduces undesirable heating and photobleaching of the specimen and provides a more repeatable fluorescent signal. An image analysis algorithm is run to locate the x-y centroid coordinates of all targeted cells in the frame by reference to features in the captured image. If there are targets in the image, the computer calculates the two-dimensional coordinates of all target locations in relation to the movable stage position  
25 and field-of-view, and then positions the galvanometer-controlled mirrors to point to the location of the first target in the first frame of cells. It should be noted that only a single frame of cells within the field-of-view has been captured and analyzed at this point. Thus, there should be a relatively small number of identified targets within this sub-population of the specimen. Moreover, because the camera is pointed to a smaller population of cells, a higher magnification is used so that each target is imaged by many pixels within the CCD camera. For example, a cluster of  
30 4, 8 16 or more pixels can be used to define a cell within the image.

Once the computer system has positioned the galvanometer controlled mirrors to point to the location of the first targeted cell within the first frame of cells, the treatment laser is fired for a brief interval so that the first targeted cell is given an appropriate dose of energy. The power sensor 446 discussed above detects the level of energy that was emitted by the treatment laser, thereby allowing the computer to calculate if it was adequate to  
35 induce a response in the targeted cell. If not sufficient, the treatment laser is fired at the same target again. If

repeated shots do not deliver the required energy dose, an error condition is communicated to the operator. These targeting, firing, and sensing steps are repeated by the computer for all targets identified in the captured frame.

Once all of the targets have been irradiated with the treatment laser in the first frame of cells, the mirrors are then positioned to the second frame of cells in the field-of-view, and the processing repeats at the point of frame illumination and camera imaging. This processing continues for all frames within the field-of-view above the scanning lens. When all of these frames have been processed, the computer instructs the movable stage to move to the next field-of-view in the specimen, and the process repeats at the back-light illumination and auto-focus step. Frames and fields-of-view are appropriately overlapped to reduce the possibility of inadvertently missing areas of the specimen. Once the specimen has been fully processed, the operator is signaled to remove the specimen, and the apparatus is immediately ready for the next specimen.

Although the text above describes the analysis of fluorescent images for locating targets, one can easily imagine that the non-fluorescent back-light LED illumination images will be useful for locating other types of targets as well, even if they are unlabeled.

The advantage of using the galvanometer mirrors to control the imaging of successive frames and the irradiation of successive targets is significant. One brand of galvanometer is the Cambridge Technology, Inc. model number 6860 (Cambridge, MA). This galvanometer can reposition very accurately within a few milliseconds, making the processing of large areas and many targets possible within a reasonable amount of time. In contrast, the movable stage is relatively slow, and is therefore used only to move specified areas of the specimen into the scanning lens field-of-view. Error signals continuously generated by the galvanometer control boards are monitored by the computer to ensure that the mirrors are in position and stable before an image is captured, or before a target is fired upon, in a closed-loop fashion.

In the context of the present invention, the term "specimen" has a broad meaning. It is intended to encompass any type of biological sample placed within the apparatus. The specimen may be enclosed by, or associated with, a container to maintain the sterility and viability of the cells. Further, the specimen may incorporate, or be associated with, a cooling or heating apparatus to keep it above or below ambient temperature during operation of the methods described herein. The specimen container, if one is used, must be compatible with the use of the illumination laser, back-light illuminator, and treatment laser, such that it transmits adequate energy without being substantially damaged itself.

One embodiment allows *in vitro* maintenance of the biological specimen in the apparatus, such that it can be monitored and processed periodically *in situ*. This is accomplished by maintaining the specimen under a standard tissue culture environment of 37 °C. In this manner, specific cells in the specimen are followed over time, periodically assessing their state, and/or periodically rendering treatment to those specific cells. The system includes software and computer memory storages for providing the apparatus with the ability to record cell locations and thereafter direct the movable stage to return to those recorded locations.

Of course, many variations of the above-described embodiments are possible, including alternative methods for illuminating, imaging, and targeting the cells. For example, movement of the specimen relative to the scanning lens could be achieved by keeping the specimen substantially stationary while the scanning lens is moved. Steering of the illumination beam, images, and energy beam could be achieved through any controllable reflective or diffractive device, including prisms, piezo-electric tilt platforms, or acousto-optic deflectors. Additionally, the apparatus can image/process from either below or above the specimen. Because the apparatus is focused through a movable scanning lens, the illumination and energy beams can be directed to different focal planes along the z-axis. Thus, portions of the specimen that are located at different vertical heights can be specifically imaged and processed by the apparatus in a three-dimensional manner. The sequence of the steps could also be altered without changing the process. For example, one might locate and store the coordinates of all targets in the specimen, and then return to the targets to irradiate them with energy one or more times over a period of time.

It should also be realized that more than one illumination laser could advantageously be provided within the cell treatment system. For example, various illumination lasers, each emitting light at a different wavelength could be used to excite labels within the specimen. Cells having one or more excited labels would then be imaged by a camera that was capable of distinguishing the wavelength of light coming from each label.

In another embodiment, multiple monochrome cameras could be used in place of a single color camera to image a plurality of excited labels. A different filter would advantageously be placed in front of each monochrome camera so that only light of one wavelength is allowed to enter the camera. The multiple images gathered by the camera array are then processed by the computer system to determine which cell or cells have been tagged with a particular label.

To optimally process the specimen, it should be placed on a substantially flat surface so that a large portion of the specimen appears within a narrow range of focus, thereby reducing the need for repeated auto-focus steps. The density of cells on this surface can, in principle, be at any value. However, the cell density should be as high as possible to minimize the total surface area required for the procedure.

The following examples illustrate the use of the described method and apparatus in different applications.

Example 1: Autologous HSC Transplantation

A patient with a B cell-derived metastatic tumor in need of an autologous HSC transplant is identified by a physician. As a first step in the treatment, the patient undergoes a standard HSC harvest procedure, resulting in collection of approximately  $1 \times 10^{10}$  hematopoietic cells with an unknown number of contaminating tumor cells. The harvested cells are enriched for HSC by a commercial immunoaffinity column (Isolex<sup>®</sup> 300, Nexell Therapeutics, Irvine, CA) that selects for cells bearing the CD34 surface antigen, resulting in a population of approximately  $3 \times 10^8$  hematopoietic cells, with an unknown number of tumor cells. The mixed population is thereafter contacted with anti-B cell antibodies (directed against CD20 and CD22) that are conjugated to phycoerythrin, and anti-CD34 antibodies that are conjugated to CyChrome<sup>™</sup>.

The mixed cell population is then placed in a sterile specimen container on a substantially flat surface near confluence, at approximately 500,000 cells per square centimeter. The specimen is placed on the movable stage of the apparatus described above, and all detectable tumor cells are identified by the presence of the phycoerythrin tag and absence of the CyChrome™ tag, and are then targeted with a lethal dose of energy from a treatment laser. The design of the apparatus allows the processing of a clinical-scale transplant specimen in under 4 hours. The cells are recovered from the specimen container, washed, and then cryopreserved. Before the cells are reinfused, the patient is given high-dose chemotherapy to destroy the tumor cells in the patient's body. Following this treatment, the processed cells are thawed at 37 °C and are given to the patient intravenously. The patient subsequently recovers with no remission of the original cancer.

#### Example 2: Allogeneic HSC Transplantation

In another embodiment, the significant risk and severity of graft-versus-host disease in the allogeneic HSC transplant setting can be combated. A patient is selected for an allogeneic transplant once a suitable donor is found. Cells are harvested from the selected donor as described in the above example. In this case, the cell mixture is contacted with phycoerythrin-labeled anti-CD3 T-cell antibodies and Texas Red®-labeled anti-CD6 antibodies. In addition, specific allo-reactive T-cell subsets are labeled using an activated T-cell marker (e.g. CyChrome™-labeled anti-CD69 antibodies) in the presence of allo-antigen. The cell population is processed by the apparatus described herein, killing cells that are CD3<sup>+</sup>CD6<sup>+</sup> and CD3<sup>+</sup>CD69<sup>+</sup>, but leaving all other cells, including CD3<sup>+</sup>CD6<sup>-</sup> and CD3<sup>+</sup>CD69<sup>-</sup> cells, unharmed. This type of control is advantageous, because administration of too many T-cells increases the risk of graft-versus-host disease, whereas too few T-cells increases the risk of graft failure and the risk of losing of the known beneficial graft-versus-leukemia effect. The present invention and methods are capable of precisely controlling the number and type of T-cells in an allogeneic transplant.

#### Example 3: Tissue Engineering

In another application, the present apparatus is used to remove contaminating cells in inocula for tissue engineering applications. Cell contamination problems exist in the establishment of primary cell cultures required for implementation of tissue engineering applications, as described by Langer and Vacanti (Langer, R. S. and Vacanti, J. P.: Tissue engineering: The challenges ahead. *Sci.Am.* 280: 86-89, 1999). In particular, chondrocyte therapies for cartilage defects are hampered by impurities in the cell populations derived from cartilage biopsies. Accordingly, the present invention is used to specifically remove these types of cells from the inocula.

For example, a cartilage biopsy is taken from a patient in need of cartilage replacement. The specimen is then grown under conventional conditions (Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L.: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N.E.J.Med.* 331: 889-895, 1994). The culture is then stained with a specific label for any contaminating cells, such as fast-growing fibroblasts. The cell mixture is then placed within the apparatus described and the labeled, contaminating cells are targeted by the treatment laser, thereby allowing the slower growing chondrocytes to fully develop in culture.

Example 4: Stem Cell Therapy

Yet another embodiment involves the use of embryonic stem cells to treat a wide variety of diseases. Since embryonic stem cells are undifferentiated, they can be used to generate many types of tissue that would find use in transplantation, such as cardiomyocytes and neurons. However, undifferentiated embryonic stem cells that are implanted can also lead to a jumble of cell types which form a type of tumor known as a teratoma (Pedersen, R. A.: Embryonic stem cells for medicine. *Sci.Amer.* 280: 68-73, 1999). Therefore, therapeutic use of tissues derived from embryonic stem cells must include rigorous purification of cells to ensure that only sufficiently differentiated cells are implanted. The apparatus described herein is used to eliminate undifferentiated stem cells prior to implantation of embryonic stem cell-derived tissue in the patient.

Example 5: Generation of Human Tumor Cell Cultures

In another embodiment, a tumor biopsy is removed from a cancer patient for the purpose of initiating a culture of human tumor cells. However, the *in vitro* establishment of primary human tumor cell cultures from many tumor types is complicated by the presence of contaminating primary cell populations that have superior *in vitro* growth characteristics over tumor cells, and the limited number of tumor cells obtainable from such a sample. For example, contaminating fibroblasts represent a major challenge in establishing many cancer cell cultures. The disclosed apparatus is used to particularly label and destroy the contaminating cells, while leaving the biopsied tumor cells intact. Accordingly, the more aggressive primary cells will not overtake and destroy the cancer cell line. The apparatus described within allows purification of cells with relatively high yield, which is particularly important in application where the starting cell number is limited. The high yield of purified cells from the disclosed apparatus provides a significant advantage over other cell purification methods.

Example 6: Generation of a Specific mRNA Expression Library

The specific expression pattern of genes within different cell populations is of great interest to many researchers, and many studies have been performed to isolate and create libraries of expressed genes for different cell types. For example, knowing which genes are expressed in tumor cells versus normal cells is of great potential value (Cossman, J. C., Annunziata, C. M., Barash, S., Staudt, L., Dillon, P., He, W.-W., Ricciardi-Castagnoli, P., Rosen, C. A., and Carter, K. C.: Reed-Sternberg cell genome expression supports a B-cell lineage. *Blood* 94: 411-416, 1999). Due to the amplification methods used to generate such libraries (e.g. PCR), even a small number of contaminating cells will result in an inaccurate expression library (Cossman et al. 1999; Schutze, K. and Lahr, G.: Identification of expressed genes by laser-mediated manipulation of single cells. *Nature Biotechnol.* 16: 737-742, 1998). One approach to overcome this problem is the use of laser capture microdissection (LCM), in which a single cell is used to provide the starting genetic material for amplification (Schutze, Lahr 1998). Unfortunately, gene expression in single cells is somewhat stochastic, and may be biased by the specific state of that individual cell at the time of analysis (Cossman et al. 1999). Therefore, accurate purification of a significant cell number prior to extraction of mRNA would enable the generation of a highly accurate expression library, one that is representative of the cell population being studied, without biases due to single cell expression or expression by contaminating cells. The methods and apparatus



described in this invention can be used to purify cell populations with high yield so that no contaminating cells are present during an RNA extraction procedure.

Within a human prostate tumor, there are multiple cell types, each of which lead to metastatic disease. To understand the basis of prostate cancer and its progression, the tools of genomics such as DNA sequencing of normal prostate and cancer prostate cDNAs (expressed sequence tags, or ESTs) and DNA array comparison of normal and cancerous tissues have been used to investigate the distinct patterns of gene expression in normal prostate and different prostate tumors. It has been shown that different prostate cell subpopulations with different surface antigens have different mRNA expression profiles. Using the apparatus disclosed within, primary human prostate tumors are purified for specific cell subpopulations to investigate their gene expression. For example, four populations of primary prostate cells are purified for mRNA analysis by binding antibodies against specific cell markers to new cell surfaces. The purified populations are: CD44<sup>+</sup>CD13<sup>-</sup> normal basal, CD44<sup>+</sup>CD13<sup>+</sup> basal cell-like cancer, CD57<sup>+</sup>CD13<sup>+</sup> normal luminal, and CD57<sup>+</sup>CD13<sup>-</sup> luminal cell-like cancer epithelial cells. Understanding the nature of each subpopulation, and its relation to disease onset and progression, could lead to new diagnostic and therapeutic approaches in the treatment of the disease.

15        Example 7: Transfection, Monitoring, and Purification of a Specific Cell Population

Many research and clinical gene therapy applications are hampered by the inability to transfect an adequate number of a desired cell type without transfecting other cells that are present. The method of the present invention would allow selective targeting of cells to be transfected within a mixture of cells. By generating a photomechanical shock wave at or near a cell membrane with a targeted energy source, a transient pore can be formed, through which genetic (or other) material can enter the cell. This method of gene transfer has been called optoporation (Palumbo, G., Caruso, M., Crescenzi, E., Tecce, M. F., Roberti, G., and Colasanti, A.: Targeted gene transfer in eukaryotic cells by dye-assisted laser optoporation. *J.Photochem.Photobiol.* 36: 41-46, 1996). The apparatus described above can achieve selective optoporation on only the cells of interest in a rapid, automated, targeted manner.

For example, bone marrow cells are plated in a specimen container having a solution containing plasmid DNA to be transfected. The plasmid DNA encodes a therapeutic gene (e.g. MDR), as well as a marker gene (e.g. green fluorescent protein). PE-labeled antibodies (anti-CD34) having specificity for stem cells are added into the medium and bind to the stem cells. The specimen container is placed within the cell processing apparatus and a first treatment laser is targeted to any cells that become fluorescent under the illumination laser light, thereby facilitating transfection of DNA specifically into the targeted cells. The cells are maintained in situ at 37 °C, all targeted cells being periodically analyzed for expression of green fluorescent protein to indicate successful transfection with the plasmid DNA. After 48 hours, all cells not expressing green fluorescent protein are eliminated with a second treatment laser, thereby yielding a pure population of stem cells expressing the transfected genes.

30        Example 8: Selection of Desirable Clones in a Biotechnology Application

In many biotechnology processes where cell lines are used to generate a valuable product, it is desirable to derive clones that are very efficient in producing the product. This selection of clones is often carried out manually,

by inspecting a large number of clones that have been isolated in some manner. The present invention would allow rapid, automated inspection and selection of desirable clones for production of a particular product. For example, hybridoma cells that are producing the greatest amounts of antibody can be identified by a fluorescent label directed against the F<sub>c</sub> region. Cells with no or dim fluorescent labeling are targeted by the treatment laser for killing, leaving  
5 behind the brightest (i.e., best producing) clones for use in antibody production.

Example 9: Automated Monitoring of Cellular Responses

Automated monitoring of cellular responses to specific stimuli is of great interest in high-throughput drug screening. Often, a cell population in one well of a well-plate is exposed to a stimulus, and a fluorescent signal is then captured over time from the cell population as a whole. Using the methods and apparatus described herein, more  
10 detailed monitoring could be done at the single cell level. For example, a cell population can be labeled to identify a characteristic of a subpopulation of cells that are of interest. This label is then excited by the illumination laser to identify those cells. Thereafter, the treatment laser is targeted at the individual cells identified by the first label, for the purpose of exciting a second label, thereby providing information about each cell's response. Since the cells are substantially stationary on a surface, each cell could be evaluated or treated multiple times, thereby providing  
15 temporal information about the kinetics of each cell's response. Also, through the use of the large area scanning lens and galvanometer mirrors, a relatively large number of wells could be quickly monitored over a short period of time.

As a specific example, consider the case of alloreactive T-cells as presented in Example 2 above. In the presence of allo-antigen, activated donor T-cells could be identified by CD69. Instead of using the treatment laser to target and kill these cells, the treatment laser could be used to examine the intracellular pH of every activated T-cell  
20 through the excitation and emitted fluorescence of carboxyfluorescein diacetate. The targeted laser allows the examination of only cells that are activated, whereas most screening methods evaluate the response of an entire cell population. If a series of such wells are being monitored in parallel, various agents could be added to individual wells, and the specific activated T-cell response to each agent could be monitored over time. Such an apparatus would provide a high-throughput screening method for agents that ameliorate the alloreactive T-cell response in graft-versus-host disease. Based on this example, one skilled in the art could imagine many other examples in which a cellular  
25 response to a stimulus is monitored on an individual cell basis, focusing only on cells of interest identified by the first label.

Although aspects of the present invention have been described by particular embodiments exemplified herein, the present invention is not so limited. The present invention is only limited by the claims appended below.

We claim:

1. An apparatus for selectively inducing a response in one or more targeted cells within a biological specimen, comprising:
  - an illumination source for illuminating a frame of cells in said biological specimen with a first wavelength of light;
  - an image capture system that captures one or more images of said frame of cells;
  - first commands for determining the locations of said one or more targeted cells within said frame of cells;
  - an energy source that emits an energy beam sufficient to induce said response in at least one of said one or more targeted cells within said frame of cells; and
  - second commands for steering said energy beam to said locations of said one or more targeted cells.
2. The apparatus of Claim 1, wherein said one or more targeted cells are identified by a first label that is activated by said first wavelength of light to emit a second wavelength of light.
3. The apparatus of Claim 2, further comprising targeted cells that are labeled with a second label, so that when said second label is activated by said first wavelength of light, said second label emits a third wavelength of light.
4. The apparatus of Claim 1, wherein said illumination source is selected from the group consisting of: a laser, an arc lamp, a light-emitting diode, an incandescent lamp, and a fluorescent lamp.
5. The apparatus of Claim 4, wherein said illumination source emits more than one wavelength of light.
6. The apparatus of Claim 2, wherein said first label is selected from the group consisting of: a monoclonal antibody, protein, lectin, carbohydrate, short peptide, membrane intercalating dye, membrane permeable reagent and genetic probe.
7. The apparatus of Claim 1, wherein said one or more targeted cells are identified by one or more cell characteristics selected from the group consisting of: size, shape, and autofluorescence.
8. The apparatus of Claim 1, wherein said one or more targeted cells are selected from the group consisting of: tumor cells, hematopoietic stem cells, T-cells, chondrocytes, fibroblasts, embryonic stem cells, teratoma-forming cells, hybridomas, and non-tumor cells.
9. The apparatus of Claim 1, wherein said image capture system comprises one or more cameras that capture said one or more images of said frame of cells.
10. The apparatus of Claim 9, wherein said one or more cameras comprise one or more color cameras that distinguish wavelengths of light emitted by labels attached to said one or more targeted cells.
11. The apparatus of Claim 9, further comprising one or more filters that distinguish labels emitting various wavelengths of light mounted in front of said one or more cameras.

12. The apparatus of Claim 9, wherein said one or more cameras capture pixel images, and said first commands comprise commands for evaluating clusters of pixels to determine the locations of said one or more targeted cells.

13. The apparatus of Claim 1, wherein said energy source comprises a laser.

14. The apparatus of Claim 13, wherein said laser emits energy having a wavelength of approximately between 100 nanometers and 30 micrometers.

15. The apparatus of Claim 1, wherein said first commands comprise commands for determining the two-dimensional locations of said one or more targeted cells within said biological specimen.

16. The apparatus of Claim 1, wherein said first commands comprise commands for determining the three-dimensional locations of said one or more targeted cells within said biological specimen.

17. The apparatus of Claim 1, wherein said response is selected from the group consisting of: cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, and excitation of a fluorescent reagent.

18. The apparatus of Claim 1, wherein said apparatus processes at least 1, 3, 5, 7, or 9 square centimeters of said biological specimen area per minute.

19. The apparatus of Claim 1, wherein said apparatus images at least 1, 3, 5, 7, or 9 million cells of said biological specimen per minute.

20. The apparatus of Claim 1, wherein said apparatus induces a response in at least 250, 500, 1,000, 2,500, 5,000, or 10,000 said targeted cells per second.

21. An apparatus for selectively inducing a response in one or more targeted cells within a biological specimen, comprising:

a first illumination source for illuminating a frame of cells in said biological specimen with a first wavelength of light;

a second illumination source for illuminating a frame of cells in said biological specimen with a second wavelength of light;

an image capture system that captures one or more images of said frame of cells;

first commands for determining the locations of said one or more targeted cells within said frame of cells;

an energy source that emits an energy beam sufficient to induce said response in at least one of said one or more targeted cells within said frame of cells; and

second commands for steering said energy beam to said locations of said one or more targeted cells.

22. The apparatus of Claim 21, wherein said first commands comprise instructions for determining the locations of said one or more targeted cells by determining the size, shape, or autofluorescence of said one or more targeted cells.

23. The apparatus of Claim 21, wherein said first commands comprise instructions for determining the locations of said one or more targeted cells by determining the presence, absence, or relative intensity of one or more labels attached to said one or more targeted cells.

24. The apparatus of Claim 21, wherein said first illumination source and said second illumination source are selected from the group consisting of: a laser, an arc lamp, a light-emitting diode, an incandescent lamp, and a fluorescent lamp.

25. The apparatus of Claim 23, wherein said one or more labels are selected from the group consisting of: monoclonal antibodies, non-antibody proteins, lectins, carbohydrates, short peptides, membrane intercalating dyes, membrane permeable reagents, or genetic probes.

26. The apparatus of Claim 21, wherein said one or more targeted cells are selected from the group consisting of: tumor cells, hematopoietic stem cells, T-cells, chondrocytes, fibroblasts, embryonic stem cells, teratoma-forming cells, hybridomas, and non-tumor cells.

27. The apparatus of Claim 21, wherein said image capture system comprises a color camera that distinguishes labels emitting various wavelengths of light.

28. The apparatus of Claim 21, wherein said image capture system comprises an array of cameras behind filters that distinguish labels emitting various wavelengths of light.

29. The apparatus of Claim 21, wherein said image capture system comprises one or more cameras mounted behind a movable array of filters that distinguish labels emitting various wavelengths of light.

30. The apparatus of Claim 21, wherein said energy source comprises a laser.

31. The apparatus of Claim 30, wherein the wavelength of energy emitted from said laser is approximately between 100 nanometers and 30 micrometers.

32. The apparatus of Claim 21, wherein said first commands comprise commands for determining the two-dimensional locations of said one or more targeted cells within said biological specimen.

33. The apparatus of Claim 21, wherein said first commands comprise commands for determining the three-dimensional locations of said one or more targeted cells within said biological specimen.

34. The apparatus of Claim 21, wherein said response is selected from the group consisting of: cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, and excitation of a fluorescent reagent.

35. An apparatus for selectively inducing a first response in a first targeted cell population and a second response in a second targeted cell population within a biological specimen, comprising:

a means for illuminating a frame of cells in said biological specimen with one or more wavelengths of light;

an image capture system that captures one or more images of said first targeted cell population and said second targeted cell population;

first commands for determining the coordinates of one or more cells within said first targeted cell population and one or more cells within said second targeted cell population by reference to said captured one or more images;

an energy source that emits an energy beam; and

5

second commands for steering said energy beam to said coordinates.

36. The apparatus of Claim 35, further comprising third commands for controlling said energy beam to induce a first response in said first targeted cell population and a second response in said second targeted cell population.

10

37. The apparatus of Claim 35, wherein said first commands comprise commands for determining the locations of fluorescently labeled cells that are excited by said one or more wavelengths of light.

38. The apparatus of Claim 35, wherein said one or more targeted cells are selected from the group consisting of: tumor cells, hematopoietic stem cells, T-cells, chondrocytes, fibroblasts, embryonic stem cells, teratoma-forming cells, hybridomas, and non-tumor cells.

15

39. The apparatus of Claim 35, wherein said image capture system comprises one or more cameras that capture said one or more images of cells.

40. The apparatus of Claim 41, wherein said energy source comprises a laser.

41. The apparatus of Claim 40, wherein the wavelength of energy emitted from said laser is approximately between 100 nanometers and 30 micrometers.

20

42. The apparatus of Claim 35, wherein said first response and said second response are selected from the group consisting of: cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, and excitation of a fluorescent reagent

43. An apparatus for monitoring the status of labeled cells within a biological sample, comprising:

an illumination source for illuminating a population of cells in said biological sample so that said labeled cells are distinguishable from non-labeled cells;

25

an image capture system that captures one or more images of said illuminated population of cells;

first commands for determining the locations of labeled cells in said one or more images;

a memory for storing the locations of said labeled cells in said biological sample;

an energy source that emits a first energy beam to illuminate a first labeled cell; and

30

a detector for measuring the fluorescence of said first labeled cell in response to illumination by said energy beam.

44. The apparatus of Claim 43, wherein said measured fluorescence of said first labeled cell is indicative of calcium flux changes, alterations in cell cycle status, alterations in cell mitotic history, changes in cell viability, changes in membrane integrity, changes in intracellular pH, alterations of transmembrane potentials, changes in glutathione reductive stage, variations in thiol activity, or changes in gene expression in said first labeled cell.

45. The apparatus of Claim 44, further comprising a second energy source for emitting a second energy beam sufficient to cause cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, or excitation of a fluorescent reagent.

5           46. The apparatus of Claim 44, further comprising second commands for repeatedly illuminating said first labeled cell and detecting the fluorescence of said first labeled cell over time.

47. A method for selectively inducing a response in one or more targeted cells within a biological specimen, comprising:

10           illuminating a frame of cells in said biological specimen with a first wavelength of light, wherein said biological specimen has been treated with one or more labels that, when excited by said first wavelength of light, emit energy at a one or more different wavelengths;

          capturing an image of said frame of cells;

          determining the locations of one or more targeted cells within said image by reference to cells that are activated by said first wavelength of light; and

15           steering an energy beam to said locations of said one or more targeted cells, wherein said energy beam is sufficient to induce a response in at least one of said one or more targeted cells.

48. The method of Claim 47, wherein determining said locations of said one or more targeted cells comprises determining the presence of, absence of, or relative intensity of said one or more labels attached to said one or more targeted cells.

20           49. The method of Claim 47, wherein capturing said one or more images of said frame of cells comprises capturing one or more images of labeled cells.

50. The method of Claim 47, wherein said response is selected from the group consisting of: cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, and excitation of a fluorescent reagent.

25           51. A method for inducing a first response in a first targeted population of cells and a second response in a second targeted population of cells, comprising:

          illuminating said first targeted population of cells and said second targeted population of cells with a first wavelength of light;

30           capturing an image comprising said illuminated first targeted population of cells and said illuminated second targeted population of cells;

          determining the locations of said first targeted population of cells by reference to said image;

          determining the locations of said second targeted population of cells by reference to said image;

and

steering an energy beam to said locations of said first targeted population of cells and said second targeted population of cells in order to induce said first response in said first targeted population of cells and said second response in said second targeted population of cells.


52. The method of Claim 51, wherein determining said locations of said first targeted population of  
5 cells comprises determining the presence of, absence of, or relative intensity of one or more labels that are attached to said first targeted population of cells.


53. The method of Claim 51, wherein determining said locations of said second targeted population of cells comprises determining the presence of, absence of, or relative intensity of one or more labels that are attached to said second targeted population of cells.

10 54. The method of Claim 51, wherein said first response and said second response are selected from the group consisting of: cell death, cell lysis, photomechanical disruption, photoablation, optoporation, activation of a photosensitive agent, inactivation of a cell component, controlled movement, and excitation of a fluorescent reagent.



1/7





3/7






FIG. 3



5/7



**FIG. 5**

6/7




FIG. 6

7/7




FIG. 7

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/07506

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b>  |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
|---|--|--|--|----|---|--|-----|--|--|-----|--|---|-----|---|--|--|--|--|--|--|
| IPC(7) : Please See Extra Sheet.<br>US CL : Please See Extra Sheet.<br>According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| <b>B. FIELDS SEARCHED</b>   |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Minimum documentation searched (classification system followed by classification symbols)<br>U.S. : 424/ 1.53, 153.1, 155.1, 577; 435/2, 40.5, 173.1, 173.4, 173.7, 288.7, 325, 347, 372; 530/391.3   |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched   |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>WEST, CHEMICAL ABSTRACTS, MEDLINE   |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| X   | HANANIA E. A Novel Automated Method of Scanning Cytometry and Laser Induced Necrosis Applied to Tumor Cell Purging. Abstract #2836. Blood. 15 November 1999, Vol. 94, No. 10, Suppl 1 Part 1. Pages 638a-639a. | 1-54   |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Y   | OH D. Phototoxicity of the Fluorescent Membrane Dyes PKH2 and PKH26 on the Human Hematopoietic KG1a Progenitor Cell Line. Cytometry. April 1999. Vol. 36, No. 4, pages 312-318.                                | 1-54   |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Y, P  | US 6,143,535 A (PAULSSON) 07 November 2000, see entire document.   | 1-54   |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| A   | US 6,007,814 A (SCHEINBERG) 28 December 1999, see entire document.   | 1-54   |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| <table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table> |  |  | * Special categories of cited documents: | *T | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | *A* document defining the general state of the art which is not considered to be of particular relevance | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | *B* earlier document published on or after the international filing date | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* | document member of the same patent family | *O* document referring to an oral disclosure, use, exhibition or other means |  |  | *P* document published prior to the international filing date but later than the priority date claimed |  |  |
| * Special categories of cited documents:  | *T   | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X*  | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| *B* earlier document published on or after the international filing date  | *Y*  | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)   | *A*  | document member of the same patent family  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Date of the actual completion of the international search<br>09 MAY 2001  |  | Date of mailing of the international search report<br>06 JUN 2001  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230   |  | Authorized officer<br>RALPH GITOMER<br>Telephone No. (703) 308-1235  |  |    |   |  |     |  |  |     |  |   |     |   |  |  |  |  |  |  |



# INTERNATIONAL SEARCH REPORT

Internal application No.  
PCT/US01/07506

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | HUANG S. Symmetry of Initial Cell Divisions Among Primitive Hematopoietic Progenitors Is Independent of Ontogenic Age and Regulatory Molecules. Blood. 15 October 1999, Vol. 94, No. 8, pages 2595-2604. | 1-54                  |
| A         | KOLLER M. Tissue Culture Surface Characteristics Influence The Expansion of Human Bone Marrow Cells. Biomaterials. 1998, Vol. 19, No. 21, pages 1963-1972.   | 1-54                  |

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/07506

### A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 35/26, 39/395, 51/00; A01N 1/02; C07K 16/00; C12M 1/34; C12N 5/00, 5/06, 5/08, 13/00; G01N 1/30

### A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/ 1.53, 153.1, 155.1, 577; 435/2, 40.5, 173.1, 173.4, 173.7, 288.7, 325, 347, 372; 530/391.3